Mantle Cell Lymphoma News and Research

RSS
Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Cancer drug offers protection against thrombosis

Cancer drug offers protection against thrombosis

FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Patrys provides update on development programme for anti-cancer product, PAT-LM1

Patrys provides update on development programme for anti-cancer product, PAT-LM1

New drug for patients with leukaemia and lymphoma puts an end to chemotherapy

New drug for patients with leukaemia and lymphoma puts an end to chemotherapy

A pill may provide hope to relapsed leukemia and lymphoma patients

A pill may provide hope to relapsed leukemia and lymphoma patients

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

FDA approves Biologics’ IMBRUVICA as oral agent for treatment of patients with CLL

FDA approves Biologics’ IMBRUVICA as oral agent for treatment of patients with CLL

Use of twice-daily pill could turn deadly blood cancer into highly treatable disease

Use of twice-daily pill could turn deadly blood cancer into highly treatable disease

IDMC recommends early stopping of Phase 3 study of ibrutinib in treatment of CLL/SLL

IDMC recommends early stopping of Phase 3 study of ibrutinib in treatment of CLL/SLL

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Acetylon announces positive preclinical data of ricolinostat (ACY-1215) in models of lymphoma

Acetylon announces positive preclinical data of ricolinostat (ACY-1215) in models of lymphoma

CAR therapy shows potential for advancing treatment of patients with ALL and CLL

CAR therapy shows potential for advancing treatment of patients with ALL and CLL

Diplomat selected as provider of IMBRUVICA capsules for MCL treatment

Diplomat selected as provider of IMBRUVICA capsules for MCL treatment

WuXi PharmaTech subsidiary enters into supply arrangement with Pharmacyclics

WuXi PharmaTech subsidiary enters into supply arrangement with Pharmacyclics

FDA approves ibrutinib for treatment of mantle cell lymphoma

FDA approves ibrutinib for treatment of mantle cell lymphoma

Imbruvica gets FDA approval for treatment of mantle cell lymphoma

Imbruvica gets FDA approval for treatment of mantle cell lymphoma